ReviewFrontiers in endocrinology2026
From pathogenic carriers to therapeutic hope: the dual role and translational prospects of exosomes in diabetic kidney disease.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease is one of the most serious microvascular complications of diabetes. Its pathogenesis is complex, and methods for early diagnosis and intervention are limited, posing major challenges in clinical practice. Exosomes, as key carriers of intercellular communication, are involved in various physiological and pathological processes, such as immune regulation, tumor metastasis, and tissue repair. The regulation of their release is closely related to disease progression and has become a hotspot in research on disease diagnosis and treatment. In diabetic kidney disease, exosomes play a dual role: on the one hand, "pathogenic exosomes", produced under pathological stimuli such as hyperglycemia, can transmit harmful substances, exacerbating kidney damage, through inflammation and fibrosis; on the other hand, "therapeutic exosomes" that are derived from stem cells or engineered otherwise, have the potential to protect and repair the kidneys. Previous reviews have predominantly concentrated on the biomarker or therapeutic potential of exosomes in diabetic nephropathy. This paper, however, systematically integrates the multifaceted roles of exosomes in the pathogenesis of diabetic nephropathy and analyses the specific application evidence of exosome-derived biomarkers across various clinical functions. It highlights the dynamic changes in exosomes during disease progression and discusses targeted intervention strategies. Additionally, it examines the opportunities and challenges in clinical translation, aiming to offer novel insights and strategies for the precise diagnosis and targeted treatment of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.